LEADERSHIP TEAM

We are a dedicated team of scientists, drug developers and entrepreneurs, racing to provide new medical possibilities to patients

Robert Habib

Robert Habib

Chief Executive Officer

Robert joined MiNA as founding Chief Executive Officer in 2013. Robert has overseen MiNA’s growth into a clinical stage company with a pipeline of new medicines and collaborations with leading pharmaceutical partners. During his tenure MiNA has established itself as the leader in saRNA therapeutics, attracting over $100m of funding. Prior to joining MiNA, Robert held roles in private equity and investment banking. He has a BSc from the University of Bristol and a MBA from Columbia Business School.

Nagy Habib

Nagy Habib

Head of R&D

Nagy is a founder and Head of R&D of MiNA Therapeutics. For over three decades Nagy has been at the forefront of clinical research and clinical practice in cancer. He pioneered the first clinical trial in the use of adenovirus and plasmid for the treatment of liver cancer, as well as the use of plasmid gene therapy in hydrodynamic gene delivery. He has published widely in gene therapy, stem cell therapy, oligonucleotides, endoscopy and surgery. Previously Nagy was founder and Chairman of EMcision Limited (acquired by Boston Scientific Inc in 2018). Nagy is Lead Clinician and Head of the Department of HPB Surgery at Imperial College London.

Peter Bains

Peter Bains

Chief Business Officer

Peter was appointed Chief Business Officer in 2020 after serving several years as a Non Executive Director. Peter brings three decades of experience in the global pharmaceutical space. Peter has held multiple leadership roles in biopharmaceuticals, most recently as Chief Executive Officer of Sosei Heptares (TSE:4565) and Syngene International (NSE:SYNGENE). Prior to this Peter held a number of roles over 23 years at GlaxoSmithKline including Head of Global Marketing and Senior VP of Commercial Development for GSK’s International Region. Peter is a Non Executive Chairman of ILC Therapeutics and Non Executive Director of Indivior (LSE:INDV).

Robin Wright

Robin Wright

Chief Financial Officer

Robin was appointed Chief Financial Officer in 2021. He has over three decades of experience in over 250 financing transactions and 170 M&A transactions, with previous CFO roles at listed biopharmaceutical companies Pharming Group NV, Karolinska Development AB and Orexo AB. Prior to this, Robin held senior roles in private equity and investment banking, including Head of European Pharma & Chemicals M&A at Citibank Salomon Smith Barney. He is a Fellow of the Institute of Chartered Accountants in England and Wales. Robin is also non-executive chairman of Vaccitech.

Troels Koch

Troels Koch

SVP, Chemistry

Troels joined MiNA in 2021 and leads chemistry research and strategy. Troels brings over 20 years of leadership in RNA therapeutics research, drug discovery and company building. He previously led RNA therapeutics research at Roche as Chief Technology Officer and VP Research, Roche Innovation Centre Copenhagen. Prior to its acquisition by Roche, Troels held the same role at Santaris where he worked for 11 years and founded its predecessor companies Cureon and Exiqon. Troels has a PhD in Bioorganic Chemistry from the University of Copenhagen.

David Blakey

David Blakey

SVP, Strategic Alliances

David joined MiNA in 2015 and leads our external research efforts. David has over 25 years of drug discovery and development experience and is an industry leader in the development of oligonucleotide therapeutics. Prior to joining MiNA David held multiple roles at AstraZeneca, most recently Chief Scientist in Oncology. David holds a Ph.D. from London University in Drug Metabolism and Toxicology and a member of the Scientific Advisory Board of the Oligonucleotide Therapeutics Society.

Julia Vassiliadou

Julia Vassiliadou

VP, Clinical Operations

Julia joined in 2021 to lead clinical operations at MiNA. She has over 20 years of clinical operations experience at GSK, most recently as Global Head, In-country Clinical Operations. Her experience spans clinical operations, study management, medical affairs and risk management. Julia gained a PhD in Reproductive Immunology from Newcastle University Medical School and undertook post-doctoral research in Human Immunology at Harvard Medical School.

Ilian Tchakov

Ilian Tchakov

VP, Clinical Development

Ilian joined in 2021 to lead clinical development at MiNA. He has over 20 years of industry and clinical development experience at Lilly, Roche, AstraZeneca and Eisai, most recently as Head of Oncology Global Early Clinical Development. Ilian’s clinical experience in oncology spans frompreclinical support through to regulatory approval. Ilian graduated with a MD from the University of Medicine in Varna and holds a number of postgraduate degrees including in pharmaceutical medicine from Cardiff and Oxford.

Kevin Fettes

Kevin Fettes

VP, CMC and Quality Operations

Kevin joined in 2021 to lead Chemistry, Manufacturing and Controls (CMC) and Quality Operations. He has over 20 years of experience in the development and manufacture of RNA oligonucleotide medicines at Nitto Denko Avecia, RXi Pharmaceuticals, Galena Biopharma, Dicerna Pharmaceuticals and most recently as an independent consultant. He gained his PhD in Organic Synthesis from the University of London. Kevin is based in Massachusetts USA.

BOARD OF DIRECTORS

Professor Nagy Habib MD, ChM, FRCS

Professor Nagy Habib MD, ChM, FRCS

Chairman and Head of R&D

Nagy is Head of R&D and Chairman of MiNA Therapeutics. For over three decades Nagy has been at the forefront of clinical research and clinical practice in cancer. He pioneered the first clinical trial in the use of adenovirus and plasmid for the treatment of liver cancer, as well as the use of plasmid gene therapy in hydrodynamic gene delivery. He has published widely in gene therapy, stem cell therapy, oligonucleotides, endoscopy and surgery. Previously Nagy was founder and Chairman of EMcision Limited (acquired by Boston Scientific Inc in 2018). Nagy is Lead Clinician and Head of the Department of HPB Surgery at Imperial College London.

Robert Habib MBA

Robert Habib MBA

Chief Executive Officer

Robert joined MiNA as founding Chief Executive Officer in 2013. Robert has overseen MiNA’s growth into a clinical stage company with a pipeline of new medicines and collaborations with leading pharmaceutical partners. During his tenure MiNA has established itself as the leader in saRNA therapeutics, attracting over $100m of funding. Prior to joining MiNA, Robert held roles in private equity and investment banking. He has a BSc from the University of Bristol and a MBA from Columbia Business School.

Peter Bains

Peter Bains

Chief Business Officer

Peter was appointed Chief Business Officer in 2020 after serving several years as a Non Executive Director. Peter brings three decades of experience in the global pharmaceutical space. Peter has held multiple leadership roles in biopharmaceuticals, most recently as Chief Executive Officer of Sosei Heptares (TSE:4565) and Syngene International (NSE:SYNGENE). Prior to this Peter held a number of roles over 23 years at GlaxoSmithKline including Head of Global Marketing and Senior VP of Commercial Development for GSK’s International Region. Peter is a Non Executive Chairman of ILC Therapeutics and Non Executive Director of Indivior (LSE:INDV).

Dr Christopher Wood MD, FRCS

Dr Christopher Wood MD, FRCS

Independent Director

Chris has more than 30 years of experience in the biotechnology sector, having founded, managed and successfully exited four companies including Bioenvision (NASDAQ:BIVN.O acquired by Genzyme), NuCana (NASDAQ:NCNA) and Medirace. Prior to this Chris was a consultant surgeon at the Royal Postgraduate Medical School. Chris is currently Executive Chairman of Thirty Technology and MedAnnex.

Dr Gur Roshwalb MD, MBA

Dr Gur Roshwalb MD, MBA

Partner, aMoon

Gur has over 20 years of healthcare industry and finance experience and is currently a Partner at aMoon. Previously Gur held CEO roles at various private and public biotechnology companies, as well as roles in venture capital at Venrock and equity research at Piper Jaffray. Gur undertook his residency training in internal medicine at Mount Sinai Medical Center where he was Chief Resident.

Kieran Johnson FCA

Kieran Johnson FCA

Group Financial Controller, Sosei Heptares

Kieran has over 20 years of finance experience in pharmaceuticals including compliance, financial accounting, management reporting, M&A and audit. Kieran is Group Financial Controller of Sosei Heptares (MOTHERS:4565). Prior to this Kieran held various roles over 15 years at GSK and 10 years at KPMG. Kieran is a Fellow of the Institute of Chartered Accountants in England and Wales.

Robert C. Kopple JD, LLM

Robert C. Kopple JD, LLM

General Partner, KF Business Ventures

Bob has practiced law in Los Angeles, CA for more than 40 years in the field of taxation and business law. As an entrepreneur, he has financed more than a dozen small companies including several involved in medical science. Bob currently sits on the Board of Directors of several biotechnology companies including Hibernation Therapeutics, Bioseal and ICL Therapeutics.

SCIENTIFIC ADVISORY BOARD

Professor John Rossi PhD

Professor John Rossi PhD

MiNA Co-Founder; Co-Director, Center for RNA Biology and Therapeutics, City of Hope

John is Dean Emeritus of the Irell and Manella Graduate School of Biological Sciences and Co-Director of the Center for RNA Biology and Therapeutics at City of Hope’s Beckman Research Institute. He is a pioneer in the field of molecular genetics and in particular small RNA biology. John founded Calando Pharmaceuticals, a wholly owned subsidiary of Arrowhead Research Corporation, and is Scientific Co-Founder of Dicerna Pharmaceuticals. John is Co-Founder of MiNA Therapeutics. In recognition of his major contributions to the field, John was appointed Honorary Board Member of the Oligonucleotide Therapeutics Society.

Professor Pål Sætrom MSc, DPhil

Professor Pål Sætrom MSc, DPhil

MiNA Co-Founder; Professor of Bioinformatics, NTNU Trondheim

Pål is Professor in Bioinformatics at the Norwegian University of Science and Technology at Trondheim. He develops and applies predictive computational models to gene regulation in a disease setting. Pål is Co-Founder of MiNA Therapeutics and Interagon AS.

Antonin de Fougerolles PhD

Antonin de Fougerolles PhD

Chief Executive Officer, Evox Therapeutics

Antonin is currently Chief Executive Officer of Evox Therapeutics. Prior to this Antonin held several senior R&D leadership roles including Chief Scientific Officer of Ablynx, Chief Scientific Officer of Moderna Therapeutics and Vice President, Research, Immunology, Metabolic, and Viral Disease at Alnylam Pharmaceuticals. After completing his PhD in Immunology at Harvard University, Antonin was a research fellow at the Wellcome Trust Immunology Unit, University of Cambridge.

Hans Huber PhD

Hans Huber PhD

Principal, BioTD Strategies, LLC

Hans is Principal of BioTD Strategies, LLC, where he advises biotechnology companies and life science investors on preclinical development strategy and evaluation of targeted drug delivery and RNA therapeutics programs and technologies. In addition, Hans is an Adjunct Associate Professor of Systems Pharmacology and Translational Therapeutics and Associate Director of The Center for Targeted Therapeutics and Translational Nanomedicine at the University of Pennsylvania. Previously, Hans held multiple roles in preclinical R&D at Merck & Co., Inc, most recently Distinguished Senior Investigator, RNA Therapeutics. Hans received his PhD in Biochemistry at the ETH Zurich and was a research fellow at Harvard Medical School.

Declan Doogan MD, FRCP

Declan Doogan MD, FRCP

Chief Medical Officer, Juvenescence

Declan is Chief Medical Officer of Juvenescence, Chairman of Biohaven Pharmaceuticals and Non Executive Director of Portage Biotech. He has more than 30 years of pharmaceutical industry experience spanning numerous roles including Chief Medical Officer at Amarin Corporation and Senior Vice President and Head of World Development at Pfizer. Declan is a Fellow of the Royal College of Physicians and the Faculty of Pharmaceutical Medicine in the United Kingdom and received his Medical degree from Glasgow University.

By continuing to use this site you are agreeing only to the use of cookies that are strictly necessary for the running of our website. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close